Pesquisa: Ipamorelin

Selective GHRP — releases growth hormone without hunger side effects

Ipamorelin Research Papers & Clinical Studies

Ipamorelin is a peptide studied for its potential therapeutic effects. Selective GHRP — releases growth hormone without hunger side effects This page indexes all published research papers, clinical trials, and scientific studies related to Ipamorelin that are available in the PepsReview research library. Each paper includes metadata such as journal name, publication year, citation count, study type, and a summary of key findings. Where available, we provide direct links to the original publication and DOI references.

Researchers can use this index to quickly locate evidence supporting specific Ipamorelin applications, compare study designs, and evaluate the strength of clinical evidence. Papers are sorted by relevance and citation count. There are currently 5 research papers indexed for Ipamorelin.

For vendor pricing, user reviews, and a complete peptide profile including mechanism of action, benefits, side effects, and regulatory status, visit the main Ipamorelin profile page.

Ipamorelin

Ipamorelin, the first selective growth hormone secretagogue

Eur J Endocrinol 1998 560 Animal Study

Ipamorelin identified as a potent pentapeptide GH secretagogue with high GH-releasing efficacy in vitro and in vivo, demonstrating selectivity for GH secretion.

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats

Growth Horm IGF Res 1999 540 Animal Study

Ipamorelin dose-dependently increased longitudinal bone growth rate (from 42 to 52 microm/day) and body weight in adult female rats over 15 days of treatment.

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

Pharm Res 1999 540 Research Article

Ipamorelin showed dose-proportional pharmacokinetics with 2-hour half-life and stimulated GH release peaking at 0.67 hours in healthy male volunteers.

Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin

Bioorg Med Chem Lett 2001 500 Research Article

Study developing hybrid compounds of NN703 and ipamorelin as highly potent growth hormone secretagogues with enhanced GH-releasing pharmacological properties.

The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism

Physiol Behav 2024 40 Research Article

Ghrelin mimetics anamorelin and ipamorelin alleviated cisplatin-induced weight loss in ferrets; anamorelin also exhibited anti-emetic effects via central mechanisms.